WEBULL
News
FBIO
3.695
+13.00%
0.425
Weekly Report: what happened at FBIO last week (0202-0206)?
Weekly Report · 9h ago
Weekly Report: what happened at FBIO last week (0126-0130)?
Weekly Report · 02/02 10:07
Weekly Report: what happened at FBIO last week (0119-0123)?
Weekly Report · 01/26 10:07
Weekly Report: what happened at FBIO last week (0112-0116)?
Weekly Report · 01/19 10:12
Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch
NASDAQ · 01/16 13:58
BUZZ-U.S. STOCKS ON THE MOVE-Albemarle, Lowe's, nLIGHT
Reuters · 01/13 15:42
Fortress Biotech Gains FDA Approval for Menkes Treatment
TipRanks · 01/13 14:49
FORTRESS BIOTECH SHARES HIT NEAR TWO-WEEK LOW, LAST DOWN 6.6%
Reuters · 01/13 14:46
Cyprium Therapeutics Wins FDA Approval for ZYCUBO in Menkes Disease
Reuters · 01/13 14:20
Fortress Biotech Announces FDA Approval For ZYCUBO, First Treatment For Menkes Disease In The U.S.
NASDAQ · 01/13 14:18
BUZZ-U.S. STOCKS ON THE MOVE-Cardinal Health, Decoy Therapeutic
Reuters · 01/13 14:06
Fortress Biotech Announces FDA Approval Of ZYCUBO For Pediatric Menkes Disease
NASDAQ · 01/13 14:01
Fortress Bio gains on FDA approval of copper replacement therapy
Seeking Alpha · 01/13 13:36
BUZZ-Fortress Biotech jumps as FDA clears first rare pediatric disease treatment
Reuters · 01/13 13:05
Fortress Biotech Announces FDA Approves Its ZYCUBO To Treat Menkes Disease In Pediatric Patients
Benzinga · 01/13 12:51
Fortress Biotech, Cyprium announce FDA approval of ZYCUBO
TipRanks · 01/13 12:50
FDA Approves Fortress Biotech’s ZYCUBO for Menkes Disease
Reuters · 01/13 12:45
FORTRESS BIOTECH INC - CYPRIUM ELIGIBLE FOR UP TO $129 MLN IN MILESTONES
Reuters · 01/13 12:45
FORTRESS BIOTECH INC - RARE PEDIATRIC DISEASE VOUCHER TO BE TRANSFERRED TO CYPRIUM
Reuters · 01/13 12:45
More
Webull provides a variety of real-time FBIO stock news. You can receive the latest news about Fortress Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBIO
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.